Pregnancy and Cardiovascular Disease by Manolis, Antonis S et al.
45 
 
EDITORIAL  
 
Pregnancy and Cardiovascular Disease 
 
Antonis S. Manolis, MD, Theodora Manolis, RN, MS, 
Sofia Metaxa, MD 
Evagelismos Hospital, Athens & Patras University 
Medical School, Patras, Greece  
 
The cardiovascular system undergoes significant 
changes during pregnancy to adapt to and accommodate 
the increased metabolic demands of the fetus and the 
mother.1-5 These adaptations produce an important 
hemodynamic burden on patients with underlying heart 
disease, and confer an increase in morbidity and 
mortality. Furthermore, pregnancy may cause specific 
cardiovascular disorders, which can impose a risk to the 
pregnant woman and to her fetus. It is estimated that in 
the western world 0.2-4% of all pregnancies are 
complicated by cardiovascular diseases (CVD).4 This risk 
is in the ascending order as the age of first pregnancy is 
increasing and as the number of cardiovascular risk 
factors is rising (e.g. smoking, hypercholesterolemia, 
diabetes, hypertension, obesity). During pregnancy, the 
most frequent cardiovascular events relate to 
hypertension (6–8%). On the other hand, in the western 
world, the most frequent CVD present during pregnancy 
is congenital heart disease-CHD (circa 75%),4,6,7 while 
rheumatic heart disease predominates in the other 
countries (circa 70%) and CHD is seen in ~15%. In 
pregnant women with heart disease, maternal death is 
estimated around 1% but it varies depending on the 
underlying CVD; neonatal complications occur in 20–
28% and neonatal mortality ranges between 1% and 4%. 
In general, CVDs are the most common cause of maternal 
death during pregnancy in the Western industrialized 
world.4 Thus, women of child-bearing age with CVD or 
cardiovascular risk factors should be counseled and 
managed early by an interdisciplinary team of 
gynecologists, cardiologists, and, when necessary, 
cardiothoracic surgeons.1,4,8  
To meet the metabolic demands of mother and fetus, 
cardiac output increases 1 L/min at 8 weeks' gestation, 
representing >50% of the total change seen, which 
culminates in an increase of cardiac output of 30-50% 
during normal pregnancy, maintained until term.9,10 
Cardiac output increases primarily because of stroke 
volume rather than heart rate, at least in early pregnancy, 
while later the heart rate also increases. By 8 weeks' 
gestation, systemic vascular resistance has fallen to 70% 
of its preconceptional value. The majority of the 
pregnancy-induced changes in these parameters occur 
during the embryonic period. Plasma volume has 
increased by ~40% at 24 weeks of gestation. Blood 
pressure falls mainly due to vasodilation, primarily 
conferred by nitric oxide and relaxin, affecting both 
systolic and diastolic components. In the third trimester, 
diastolic pressure gradually rises and may normalize to 
baseline values at term. Another important aspect of the 
cardiovascular status in pregnancy relates to hemostatic 
changes, which lead to hypercoagulability via an increase 
in concentration of coagulation factors, fibrinogen, and 
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platelet adhesiveness, and a concomitant diminution of 
endogenous fibrinolysis. In addition, mechanical 
obstruction to venous return by the enlarged uterus can 
cause stasis which enhances the thromboembolic risk.4  
During labor and delivery, particularly when the uterus is 
contracting, a further increase occurs in cardiac output, 
oxygen consumption and blood pressure; these 
hemodynamic changes are influenced by the mode of 
delivery.10 Cardiac output is also increased during the 
early postpartum period as additional blood reaches the 
circulation from the contracting uterus producing a 
preload increase, rendering at-risk patients susceptible to 
developing pulmonary edema at this stage. Hemodynamic 
conditions mostly return to normal within 1–3 days after 
delivery but in some women this may take up to a week. 
 
Diagnosis of CVD 
All diagnostic approaches start with a detailed history 
and a complete physical examination which may 
contribute to rendering a diagnosis or a suspicion of CVD 
prior to resorting to other more expensive tests.4 An 
electrocardiogram (ECG) and / or Holter monitor may 
provide further clues for structural and electrical 
disorders. Echocardiography, not involving exposure to 
radiation, has become the screening method of choice, as 
well as a most important diagnostic tool during pregnancy 
for initial diagnosis and follow-up. Transesophageal 
echocardiography is a semi-invasive method, less often 
needed, but capable of better studying complex CHD. 
Exercise testing is important to assess functional capacity, 
chronotropy and exercise-induced arrhythmias; stress 
echocardiography and myocardial scintigraphy should be 
avoided. In patients with known CVD, exercise testing 
should be performed prior to pregnancy for risk 
evaluation. Invasive testing and procedures should be 
avoided, if possible, or used with extra caution and 
exposure to radiation should be “as low as reasonably 
achievable” (“ALARA”). Fetal assessment with use of 
ultrasound is most important. Congenital cardiac 
malformations can thus be diagnosed as early as the 13th 
week, with optimal timing between 18-22 weeks.  
Interventions in a pregnant woman should be limited 
to those absolutely necessary with provision for minimal 
radiation exposure and measures to protect and shield the 
fetus; best timing would be after the 4th month in the 2nd 
trimester, when organogenesis is complete, the thyroid 
still inactive and the uterus still small.  
 
Risk Assessment 
Pre-pregnancy risk assessment and counselling is 
indicated in all women with known or suspected 
congenital or acquired cardiovascular and aortic disease.4 
The risk of pregnancy depends on the specific type of 
heart disease and clinical and functional status of the 
patient. Women with significant CVD should be managed 
jointly by an obstetrician and an experienced cardiologist. 
Risk assessment can be based on predictors that have 
been identified in studies that included large populations 
with a variety of CVD. Several risk scores have been 
developed based on these predictors, of which the 
CARPREG risk score (Toronto group risk score) is most 
widely known and used. This risk score has been 
validated in several studies and appears valuable to 
predict maternal risk, although overestimation can occur.4 
The CARPREG risk score includes acquired and 
congenital heart disease and comprises 4 items, each 
receiving 1 point: prior arrhythmias or cardiac event, 
New York heart Association (NYHA) functional class >II 
or cyanosis, left heart obstruction, and systemic 
ventricular dysfunction (ejection fraction < 40%).11 With 
0 points, the risk is estimated at 5%; with 1 point it rises 
to 27%; and with >1 points the risk is prohibitive at 75%. 
The ZAHARA I risk score is more comprehensive, albeit 
it relates to congenital heart disease only, and enlists 8 
items to consider: prior arrhythmias, NYHA functional 
class >II, left heart obstruction, cardiac medication before 
pregnancy, systemic atrioventricular (AV) valve 
regurgitation, pulmonary AV valve regurgitation, 
mechanical valve prosthesis, and cyanotic heart disease.12 
Details of this scoring system can be viewed in Table 1. 
 
Table 1. ZAHARA Prediction Score 
 
Predictors Points  Total Points Risk 
Prior arrhythmias 1.5  0 2.9% 
NYHA class >II 0.75  0.5-1.5 7.5% 
Left heart obstruction 
(PG >50 mmHg or AVA <1 
cm2)
2.5  1.51-2.50 17.5% 
Cardiac medication 
before pregnancy 
1.5  2.51-3.50 43.1% 
Systemic AV valve 
regurgitation 
0.75  >3.51 70% 
Pulmonary AV valve 
regurgitation 
0.75  
Mechanical valve 
prosthesis 
4.5  
Cyanotic heart disease 
(corrected / uncorrected) 
1.0  
 
AV = atrioventricular; AVA = aortic valve area; NYHA = New York 
Heart Association; PG = peak gradients 
 
However, the European Task Force recommends that 
maternal risk assessment should be performed according 
to the modified World Health Organization (WHO) risk 
classification (Table 2).4 This risk classification includes 
the underlying maternal heart disease and specifies 
contraindications for pregnancy that are not incorporated 
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in the CARPREG and ZAHARA risk scores. Women in 
WHO class I have a very low risk requiring limited 
cardiology follow-up. Those in WHO class II are at low 
or moderate risk, and need follow-up every trimester. For 
women in WHO class III, there is a high risk of 
complications, and frequent, monthly or bimonthly, 
cardiology and obstetric follow-up is advised. Women in 
WHO class IV should be advised against pregnancy but, 
if they become pregnant and will not consider 
termination, close (e.g. monthly) follow-up will be 
needed. In pregnant women with heart disease, as 
mentioned earlier, neonatal complications occur in 20–
28% and neonatal mortality ranges between 1% and 4%. 
Maternal predictors of neonatal events include: baseline 
NYHA class >II or cyanosis; maternal left heart 
obstruction; smoking during pregnancy; multiple 
gestation; use of oral anticoagulants during pregnancy, 
and; mechanical valve prosthesis.4  
 
Table 2. Modified World Health Organization (WHO) 
Risk Classification 
Class Risk Conditions 
I No detectable ↑ risk 
of maternal 
mortality & no/mild 
↑ in morbidity 
• Uncomplicated, small or mild:  
√ pulmonary stenosis; √ PDA; √ MVP 
• Successfully repaired simple lesions 
(ASD or VSD, PDA, anomalous 
pulmonary venous drainage). 
• Atrial or ventricular ectopic beats, 
isolated 
II Small ↑ risk of 
maternal mortality 
or moderate ↑ in 
morbidity 
• Unoperated ASD or VSD 
• Repaired tetralogy of Fallot 
• Most arrhythmias 
  WHO II–III (depending on individual) 
• Mild LV impairment 
• Hypertrophic CM  
• Native or tissue VHD not considered 
WHO I or IV 
• Marfan syndrome without aortic 
dilatation 
• Aorta <45 mm in aortic disease 
associated with bicuspid aortic valve 
• Repaired coarctation 
III Significantly ↑ risk 
of maternal mortali-
ty or severe morbi-
dity. Expert counse-
lling required. If 
pregnancy is 
decided upon, 
intensive specialist 
cardiac & obstetric 
monitoring needed 
throughout pregna-
ncy, childbirth, & 
puerperium  
• Mechanical valve 
• Systemic RV 
• Fontan circulation 
• Cyanotic heart disease (unrepaired) 
• Other complex CHD 
• Aortic dilatation 40–45 mm in Marfan 
syndrome 
• Aortic dilatation 45–50 mm in aortic 
disease associated with bicuspid aortic 
valve 
IV Extremely ↑ risk of 
maternal mortality 
or severe morbidity; 
pregnancy 
contraindicated. If 
pregnancy occurs 
termination should 
be discussed. If 
pregnancy 
continues, care as 
for class III. 
• Pulmonary arterial hypertension of any 
cause 
• Severe systemic ventricular dysfunction 
(LVEF <30%, NYHA III–IV) 
• Previous peripartum CM with any 
residual impairment of LV function 
• Severe MS, severe symptomatic AS 
• Marfan syndrome with aorta dilated >45 
mm 
• Aortic dilatation >50 mm in aortic 
disease associated with bicuspid AoV 
• Native severe coarctation 
 
AS = aortic stenosis; AoV = aortic valve; ASD = atrial septal defect; 
CHD = congenital heart disease; CM = cardiomyopathy; LV = left 
ventri-cle(-ular); LVEF = left ventricular ejection fraction; MS = 
mitral stenosis; MVP = mitral valve prolapse; NYHA = New York 
Heart Association; PDA = patent ductus arteriosus; RV = right 
ventricle; VHD = valvular heart disease; VSD = ventricular septal 
defect 
 
Pregnancy Complications and CVD 
Epidemiological and other studies indicate that in 
women presenting with severe preeclampsia, functional, 
biochemical, and familial cardiovascular risk markers 
may contribute to later development of CVD. Recurrent 
abortion may be a potential risk factor for CVD in this 
patient population.13,14 In a significant number of women 
with a history of severe preeclampsia and spontaneous 
recurrent abortions, endothelial dysfunction may be 
present, as characterized by a lower endothelium-
mediated vasodilatation and lower blood nitrites. It is 
suggested that endothelial dysfunction may be a 
triggering mechanism for both preeclampsia and recurrent 
abortions, as well as a risk for future development of 
CVD.14 Based on these findings, an exciting hypothesis 
has been put forth that interventions to correct the 
endothelial dysfunction early in pregnancy may help 
prevent obstetric complications emanating from 
placentation-related disorders and also may finally 
ameliorate the cardiovascular risk later in life. It has been 
reported that supplementation with L-arginine during 
pregnancy may confer significant improvement of the 
reproductive outcome in women with endothelial 
dysfunction diagnosed preconceptionally or in early 
pregnancy.14,15  
Gestational dysglycemia, even in its milder forms, 
identifies a group of women who are at increased risk not 
only for type 2 diabetes mellitus but also for an earlier 
age of onset of CVD.16 Furthermore, much of that risk, 
expressed as dysglycemia, metabolic syndrome, and 
altered vascular physiology, may become evident in the 
first few months postpartum. Identifying a dysglycemic 
pregnancy and hence a population of women at increased 
subsequent cardiometabolic risk enables clinicians to 
modify such conditions and thus attenuate adverse long-
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term outcomes, particularly cardiovascular risk, by 
targeted intervention. Future research may identify and 
validate potential useful postpartum screening tools and 
biomarkers of subsequent vascular risk, including altered 
endothelial responsiveness, which may be evident before 
diabetes, metabolic syndrome, or cardiovascular events 
emerge.16  
 In a recent study, among women pregnant at least 
once, a cohort of women was identified with miscarriages 
or stillbirths.17 Among 1,031,279 such women followed 
for an average of 15 years per woman, 2798 myocardial 
infarctions (MIs), 4053 strokes, and 1269 cases of 
renovascular hypertension were detected. Women with 
stillbirths had 2.7, 1.7, and 2.4 times the rates of MI, 
strokes, and renovascular hypertension, respectively, as 
women with no stillbirths. Compared with women with 
no miscarriages, women with miscarriages had 1.13, 1.16, 
and 1.20 times the rates of these same outcomes, 
respectively; more miscarriages increased these rates 
significantly. Associations were strongest in younger 
women (<35 years). The authors concluded that 
pregnancy losses were associated with subsequent risks 
of MI, strokes, and renovascular hypertension, conditions 
linked to atherosclerosis, making pregnancy loss a 
possible candidate risk factor for atherosclerotic disease 
in women, with possible inflammatory processes being 
the common denominator.17   
 In another case-control study, in a Dutch population, it 
was found that women with pregnancies complicated by 
preeclampsia or intrauterine growth restriction and their 
mothers have high-risk cardiovascular profiles with 
higher glucose levels, prevalence of hypertension, and 
larger waist circumferences compared with women with 
uncomplicated pregnancies and their mothers.18 The 
authors concluded that vascular-related pregnancy 
complications may confer higher risk for future 
development of CVD. According to the AVON study in a 
prospective cohort of 3416 British women, pregnancy 
was an important opportunity for early identification of 
women at increased risk of CVD later in life.19 
Specifically, in that study hypertensive disorders of 
pregnancy and pregnancy diabetes mellitus were 
independently associated with an increased calculated 10-
year CVD risk. Preeclampsia appeared to be a better 
predictor of future CVD because it was associated with a 
wider range of cardiovascular risk factors.19 Similar were 
the findings of a case-control study, whereby in a cohort 
of 325 women with hypertension in pregnancy, mortality 
from ischemic heart disease was more common in these 
hypertensive women (24.3%) compared with 629 
normotensive women (14.6%; relative risk-RR 1.66).20 
Cerebrovascular event deaths occurred in 9.5% of cases 
and in 6.5% of controls (RR 1.46). Survival times were 
shorter on average by 3-9 years as a consequence of 
CVD. The authors concluded that there was an increased 
risk of death from ischemic heart disease and 
cerebrovascular events over long-term follow-up among 
women who suffered from hypertension in pregnancy. 
 However, the results of a Norwegian population-based 
study (HUNT), indicated that cardiovascular risk factors 
that are present before a hypertensive pregnancy are more 
important determinants of subsequent cardiovascular risk 
factors than the hypertensive pregnancy itself.21 
Specifically, the study assessed whether the increased risk 
that preeclampsia and hypertension confer later in life can 
be attributed to factors that operate in pregnancy or to 
prepregnancy risk factors that are shared by both 
disorders. Among 3225 women with a singleton birth, 
those who experienced preeclampsia or gestational 
hypertension in pregnancy had significantly higher levels 
of body mass index and systolic and diastolic blood 
pressures and unfavorable lipids compared with other 
women. However, after adjustment for prepregnancy 
measurements, the difference in body mass index was 
attenuated by >65%, and the difference in blood pressure 
by circa 50%. In relation to high-density lipoprotein 
cholesterol and triglycerides, differences between the 
groups were attenuated by 40% and 72%, respectively. 
The authors concluded that the positive association of 
preeclampsia and gestational hypertension with 
postpregnancy cardiovascular risk factors could be due 
largely to shared prepregnancy risk factors rather than 
reflecting a direct influence of the hypertensive disorder 
in pregnancy.21  
A study of singleton first births (129,920 deliveries) 
investigated whether pregnancy complications associated 
with low birthweight were related to risk of subsequent 
ischemic heart disease in the mother over 15-19 years of 
follow-up.22 Maternal risk of admission for ischemic 
heart disease or death was associated with delivering a 
baby in the lowest birthweight quintile for gestational age 
(adjusted hazard ratio-HR 1.9), preterm delivery (HR 
1.8), and pre-eclampsia (HR 2.0). The associations were 
additive; women with all three characteristics had a risk 
of ischemic heart disease admission or death 7 times 
greater than the reference category. The authors 
concluded that complications of pregnancy associated 
with low birthweight confer an increased risk of 
subsequent ischemic heart disease in the mother. 
Common genetic risk factors might explain the link 
between birthweight and risk of ischemic heart disease in 
both the individual and the mother.  
 The incidence of pregnancy-related acute myocardial 
infarction (MI) is quite low, estimated at 3–10 per 
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100,000 deliveries.23,24 However, pregnancy increases the 
risk of MI by 3–4 fold. In general, the incidence of 
coronary artery disease and MI is increasing among 
pregnant women, most likely as a result of the increased 
frequency of smoking among women. Although MI is 
rare in pregnancy, when it occurs it is associated with a 
disproportionately high maternal mortality rate reaching 
5–37%. The risk of death from MI increases as pregnancy 
advances, with a mortality rate in the first and second 
trimester reported at ~25%, in the third trimester ~40%, 
and if the MI occurs in the peripartum period, the 
mortality rate may increase to 50%.23 Risk factors that 
predispose to MI are smoking, maternal age, familial 
hypercholesterolemia, hypertension and diabetes mellitus. 
Pregnancy is known to be associated with an increased 
probability of developing hypertension (preeclampsia, 
eclampsia) or for the worsening of pre-existing 
hypertension. The diagnosis of MI in pregnancy may be 
difficult and is challenging for several reasons; due to its 
rarity, MI may not be considered in a young apparently 
healthy female, while the physiological alterations of 
pregnancy may mask or mimic the signs and symptoms 
of MI, such as dyspnea, palpitations, fatiguability, nausea 
and heart burn, epigastric or chest pain (attributed to 
gastro-esophageal reflux), peripheral edema, distended 
neck veins, and the presence of a third heart sound and 
ejection systolic murmur.23  
 Pregnancy-associated plasma protein-A (PAPP-A) is 
one of the circulating proteins in the maternal plasma, 
which is also present in unstable plaques. Elevated levels 
of PAPP-A in pregnancy may reflect instability of 
atherosclerotic plaques. PAPP-A is a new candidate 
marker of unstable angina and acute MI and may have 
diagnostic value in unstable angina or acute MI during 
pregnancy.23 The utilization of PAPP-A in coronary 
artery disease in pregnancy may be of particular value in 
patients with negative troponin testing; PAPP-A seems to 
be associated with inflammation and might be used to 
detect plaque instability and rupture before an increase in 
cardiac troponin is detectable.23   
 A US population-based study assessed the incidence, 
mortality, and risk factors for pregnancy-related acute 
MI.25 The incidence of MI was estimated at 6.2 per 100 
000 deliveries with a mortality of 5.1% (44/859). The 
odds of acute MI were 30-fold higher for women aged 
>40 years than for women <20 years of age. Important 
risk factors for pregnancy-related acute MI included 
hypertension (odds ratio - OR 21.7), thrombophilia (OR 
25.6), diabetes mellitus (OR 3.6), smoking (OR 8.4), 
transfusion (OR 5.1), postpartum infection (OR 3.2), and 
age >30 years. The authors concluded that although acute 
MI is a rare event in women of reproductive age, 
pregnancy increases the risk 3- to 4-fold.25  
Some of the risk factors and/or mechanisms for 
pregnancy-related acute MI may be unique to pregnancy. 
Coronary artery dissection is a rare cause of acute MI; 
however, in one series, this mechanism involved 20% of 
women who had recently delivered.26 Postpartum 
degeneration of the ground substance of the connective 
tissue in the intima and media of the coronary arteries has 
been proposed as a mechanism.27 In another series, 
findings of coronary artery anatomy in 68 of 125 cases of 
pregnancy-related acute MI revealed coronary artery 
dissection in 16%, coronary thrombus without athero-
sclerotic disease in 21%, normal coronaries in 29%, and 
atherosclerosis with or without intracoronary thrombus in 
43% of the cases.28 In contrast, the majority of cases of 
acute MI outside of pregnancy are due to coronary 
thrombosis overlying a ruptured atherosclerotic plaque.  
Finally, women with an implantable cardioverter 
defibrillator (ICD) device who become pregnant do not 
have any additional risk apart from that conferred from 
their underlying heart disease and the presence of the 
device does not seem to pose any extra risk to the fetus.29  
 
Management of Coronary Heart Disease During 
Pregnancy 
Beta-1 selective beta-blockers are the drugs of choice 
for coronary heart disease during pregnancy.4 Nitrates can 
also be used in symptomatic patients. Antiplatelet therapy 
with aspirin as secondary prevention is controversial, due 
to the increased risk of hemorrhage. However, it should 
be administered in case of percutaneous coronary 
intervention (PCI) and stenting and also following MI. 
Data on use of clopidogrel remain insufficient. 
Angiotensin converting enzyme (ACE) inhibitors and 
statins are not considered safe. For the management of 
acute MI, coronary angiography with possible PCI is 
preferable to thrombolysis, particularly when spontaneous 
dissection of the coronary arteries is suspected. Bare 
stents should be used where possible. Great caution 
should be exercised during the first trimester, when 
meticulous risk/benefit analysis is warranted, due to the 
potential harm to the fetus. Thrombolytics are probably 
not teratogenic, as these drugs do not generally cross the 
placental barrier; however, they confer an increased risk 
of bleeding. 
 
Peri-Partum Cardiomyopathy (CM) 
Heart failure associated with pregnancy has been 
described in women with a distinct type of 
cardiomyopathy, designated as peri-partum or pregnancy-
associated cardiomyopathy (CM). Initially considered to 
occur during the last gestational month and first 5 months 
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after delivery, later data indicate that women may present 
with CM earlier during pregnancy.30 A potential 
detrimental effect of subsequent pregnancy on the 
outcome of these patients has been reported and thus the 
advice is to avoid subsequent pregnancies. The disease 
can affect women of various ethnic backgrounds at any 
age but it appears more common in women >30 years of 
age. A strong association of the disease with gestational 
hypertension and twin pregnancy has been noted and thus 
the suspicion should be higher in these women. Severe 
left ventricular dysfunction has been noted upon 
diagnosis of the disease, albeit it normalizes in more than 
half of the patients, especially in women with a left 
ventricular (LV) ejection fraction (LVEF) >30% at the 
time of diagnosis. Early recognition of peri-partum CM is 
important as it may lead to timely initiation of 
anticongestive and supportive therapy, and better care and 
outcome of this life-threatening condition. With the 
recent discovery of a possible key role of oxidative stress 
and the generation of a cardiotoxic subfragment of 
prolactin in the pathophysiology of peripartum CM, 
pharmacological blockade of prolactin with use of 
bromocriptine may offer a novel approach for a disease-
specific therapy.31,32  
 
Exercise in Pregnancy 
In 2002, the American College of Obstetricians and 
Gynecologists published exercise guidelines for 
pregnancy, which suggested that in the absence of 
medical or obstetric complications, 30 minutes or more of 
moderate exercise a day on most, if not all, days of the 
week is recommended for pregnant women.33 Recent 
research has determined that increasing physical activity 
energy expenditure to a minimum of 16 metabolic 
equivalent task (MET) hours per week, or preferably 28 
MET hours per week, and increasing exercise intensity to 
≥60% of heart rate reserve during pregnancy, reduces the 
risk of gestational diabetes mellitus and perhaps 
hypertensive disorders of pregnancy (i.e. gestational 
hypertension and pre-eclampsia) compared with less 
vigorous exercise.34 To achieve this more rigorous 
exercise program, one could walk at 3.2 km per hour for 
11.2 hours per week (2.5 METs, light intensity), or 
preferably exercise on a stationary bicycle for 4.7 hours 
per week (∼6-7 METs, vigorous intensity).34 Light 
muscle strengthening performed over the second and 
third trimester of pregnancy has minimal effects on a 
newborn infant's body size and overall health.  
 
Pregnancy in Women with Structural Heart Disease 
In 2007, the European Registry on Pregnancy and 
Heart disease was initiated by the European Society of 
Cardiology enrolling pregnant women with valvular, 
congenital or ischemic heart disease, or cardiomyopathy 
(CM). Recent data from this registry of 1321 pregnant 
women with most patients being in NYHA class I (72%), 
indicated that congenital heart disease (66%) was most 
prevalent; other structural heart disease included valvular 
disease in 25%, CM in 7%, and ischemic heart disease in 
2%.7 Maternal death was at 1%, compared with 0.007% 
in the normal population. Highest maternal mortality was 
found in patients with CM (2.4%). During pregnancy, 
there were 338 hospitalizations (26%), mostly for heart 
failure (n=133). Caesarean section was performed in 
41%. Fetal mortality was 1.7% and neonatal mortality 
0.6%, both higher than in the normal population (0.35% 
and 0.4% respectively). In centers of developing 
countries, maternal and fetal mortality was higher than in 
developed countries (3.9 vs. 0.6%, P < 0.001 and 6.5 vs. 
0.9% P < 0.001). The authors concluded that the majority 
of patients can safely complete pregnancy and delivery as 
long as adequate pre-pregnancy evaluation & specialized 
high-quality care during pregnancy and delivery are 
available. Pregnancy outcomes were markedly worse in 
patients with CM and in developing countries.  
The adverse effect and prognosis that CM confers in 
pregnant women was also confirmed in a study of 36 
pregnancies in 32 women with dilated CM.35 A total of 
39% (14 of 36) of the pregnancies were complicated by at 
least 1 maternal cardiac event. Moderate or severe LV 
dysfunction and/or NYHA functional class III or IV (p = 
0.003) were the main determinants of adverse maternal 
cardiac outcomes during pregnancy; 16-month event-free 
survival was worse in pregnant women compared with 
nonpregnant women (28 + 11% vs. 83 + 10%, p = 0.02). 
The adverse neonatal event rate was highest among 
women with obstetric and cardiac risk factors (43%). The 
authors concluded that in pregnant women with dilated 
CM the risk of adverse cardiac events is significant; pre-
pregnancy characteristics can identify women at the 
highest risk. Pregnancy seems to have a short-term 
negative impact on the clinical course in women with 
dilated CM.  
 
Pregnancy in Women with Congenital Heart Disease  
A special group of patients are those with congenital 
heart disease (CHD) reaching child bearing age and 
wishing to pursue pregnancy.6,36-38 Progress in diagnosis 
and management of CHD over the years has improved the 
long-term outcome of these patients and rendered 
possible this scenario.6,38 However, pregnancy, as 
outlined above, imposes a circulatory burden, mainly due 
to volume overload, having an impact on a healthy 
mother and, of course, an even greater risk on a mother 
with CHD placing both the mother and the fetus at great 
51 
 
risk. In this setting the risk of pregnancy varies according 
with the underlying disease and the clinical condition of 
the mother.38 It thus becomes imperative to have a risk 
assessment performed before pregnancy. Risk scores 
have been proposed to make this possible (see previous 
discussion and Tables 1 & 2).  
 Overall the percentage of cardiac complications during 
pregnancy in this group is estimated ~11%. The most 
frequent cardiac complication appears to be the 
development of heart failure (~5%), with patients with 
complex CHD (Eisenmenger, other cyanotic CHD, 
pulmonary atresia with ventricular septal defects) being at 
highest risk.38 The second most common problem appears 
to be cardiac arrhythmias, mostly supraventricular, but 
also ventricular and occasional bradyarrhythmias. 
Cardiovascular events (~1 in 50 pregnancies), including 
death, MI, or stroke may be encountered mainly in 
patients with Eisenmenger syndrome and those with 
palliated or uncorrected cyanotic heart disease.  
 Obstetric complications may include hypertensive 
disorders (eclampsia) observed with about the same 
incidence (~9%) as in the general population (8%), and 
the “hemolysis elevated liver enzymes low platelets” 
syndrome. Preeclampsia and eclampsia may be more 
prevalent (13-16%) in patients with transposition of the 
great vessels, pulmonic stenosis, aortic coarctation, and 
pulmonary atresia with ventricular septal defects. 
Thromboembolic events have also been reported in ~2% 
of pregnancies. With regards to fetal complications, 
offspring mortality may be ~ 4% (vs 1% in the general 
population), ascribed in part to the relatively high overall 
premature birth rate (16%) and the recurrence of CHD, 
the latter depending on the type of CHD, ranging between 
0.6% for the transposition patients and 8% for patients 
with AV septal defects.37 Particularly high rates of 
premature delivery and/or CHD recurrence are observed 
in patients with Eisenmenger syndrome (~28%).  
 
Guidelines on the Management of CVD During 
Pregnancy 4, 39 
Recommendations for the management of congenital 
heart disease (CHD): 
● Balloon valvulotomy should be performed before pre-
gnancy to relieve severe pulmonary valve stenosis (peak 
gradient by Doppler >64 mmHg) (Class I / Level B) 
● Follow-up should be individualized: from twice during 
pregnancy to monthly (Class I / Level C) 
● Patients with Ebstein’s anomaly with symptoms of 
cyanosis and/or heart failure should be treated before pre-
gnancy or advised against pregnancy (Class I / Level C) 
● In severe pulmonary regurgitation, pulmonary valve 
replacement (bioprosthesis) should be performed before 
pregnancy in symptomatic women with marked dilatation 
of the right ventricle (Class I / Level C) or considered in 
asymptomatic women (Class IIa / Level C) 
● All women with a bicuspid aortic valve should undergo 
imaging of the ascending aorta before pregnancy, and 
surgery should be considered when the aortic diameter is 
>50 mm (Class IIa / Level C) 
● Anticoagulation should be considered during pregnancy 
in Fontan patients (Class IIa / Level C) 
● In pulmonary artery hypertension (PAH), 
anticoagulation should be considered in patients with 
suspicion of pulmonary embolism as the cause of or 
contributor to the PAH (Class IIa / Level C) 
● In patients already taking drug therapy for PAH before 
pregnancy, continuation may be considered after 
informing about the teratogenic effects (Class IIa/Level C) 
● Women with the following conditions should be 
advised against pregnancy: pulmonary hypertension; 
oxygen saturation <85% at rest; patients with 
transposition of the great vessels (TGA) and a systemic 
right ventricle with more than moderate impairment of 
right ventricular function and/or severe tricuspid 
regurgitation; Fontan patients with depressed ventricular 
function and/or moderate to severe AV valvular regurgi-
tation or with cyanosis or with protein-losing enteropathy 
 
Recommendations for the management of aortic 
disease:4,40  
● Women with Marfan syndrome or other known aortic 
disease should be counselled about the risk of aortic 
dissection during pregnancy and the recurrence risk for 
the offspring (Class I / Level C) 
● Imaging of the entire aorta (CT/MRI) should be perfo-
rmed before pregnancy in patients with Marfan syndrome 
or other known aortic disease (Class I / Level C) 
● Women with Marfan syndrome and an ascending aorta 
>45 mm should be treated surgically before pregnancy 
(Class I / Level C) 
● In pregnant women with known aortic dilatation, 
(history of) type B dissection or genetic predisposition for 
dissection, strict blood pressure control is recommended 
(Class I / Level C) 
● Repeated echocardiographic imaging every 4–8 weeks 
should be performed during pregnancy in patients with 
ascending aorta dilatation (Class I / Level C) 
● For imaging of pregnant women with dilatation of the 
distal ascending aorta, aortic arch or descending aorta, 
MRI (without gadolinium) is recommended (Class I/Level C) 
● In women with a bicuspid aortic valve, imaging of the 
ascending aorta is recommended (Class I / Level C) 
● In patients with an ascending aorta <40 mm, vaginal 
delivery is favored (Class I / Level C) 
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● Women with aortic dilatation or (history of) aortic 
dissection should deliver in a center where cardiothoracic 
surgery is available (Class I / Level C) 
● In patients with an ascending aorta >45 mm, caesarean 
delivery should be considered (Class I / Level C) 
● Surgical treatment pre-pregnancy should be considered 
in women with aortic disease associated with a bicuspid 
aortic valve when the aortic diameter is >50mm (or >27 
mm/m2 BSA) (Class IIa / Level C) C 
● Prophylactic surgery should be considered during 
pregnancy if the aortic diameter is ≥50 mm and 
increasing rapidly (Class IIa / Level C) 
● In Marfan, and other patients with an aorta 40–45 mm, 
vaginal delivery with epidural anesthesia and expedited 
second stage should be considered (Class IIa / Level C) or 
alternatively caesarean section may be considered (Class 
IIb / Level C)  
● Patients with (or history of) type B dissection should be 
advised against pregnancy. 
 
Recommendations for the management of valvular heart 
disease:4,41,42   
Mitral stenosis (MS) 
●In patients with symptoms or pulmonary hypertension: 
restricted activities and β1-selective blockers (Class I / 
Level B) 
● Diuretics when congestive symptoms persist despite β-
blockers (Class I / Level B) B 64 
● Patients with severe MS should undergo intervention 
before pregnancy (Class I / Level C) C 
● Anticoagulation in the case of atrial fibrillation (AF), 
left atrial thrombosis, or prior embolism (Class I / Level C)  
● Percutaneous mitral commissurotomy should be 
considered in pregnant patients with severe symptoms or 
systolic pulmonary artery pressure >50 mmHg despite 
medical therapy (Class IIa / Level C) 
 
Aortic stenosis (AS) 
● Patients with severe AS should undergo intervention 
pre-pregnancy if: they are symptomatic (Class I / Level B); 
or LV dysfunction (LVEF <50%) is present (Class I / 
Level C) 
● Asymptomatic patients with severe AS should undergo 
intervention pre-pregnancy when they develop symptoms 
during exercise testing (Class I / Level C)  
● Asymptomatic patients with severe AS should be 
considered for intervention pre-pregnancy when a fall in 
blood pressure below baseline during exercise testing 
occurs (Class IIa / Level C)  
 
Regurgitant lesions 
● Patients with severe aortic or mitral regurgitation and 
symptoms or impaired ventricular function or ventricular 
dilatation should be treated surgically pre-pregnancy 
(Class I / Level C)  
● Medical therapy is recommended in pregnant women 
with regurgitant lesions when symptoms occur (Class I / 
Level C) 
 
Mechanical valves 4, 42C 
● Oral anticoagulants (OACs) are recommended during 
the second and third trimesters until the 36th week (Class I 
/ Level C)  
● Change of anticoagulation regimen during pregnancy 
should be done in hospital (Class I / Level C)  
● If delivery starts while on OACs, caesarean delivery is 
indicated (Class I / Level C)  
● OAC should be discontinued and dose-adjusted 
unfractionated heparin (UFH) (a PTT ≥2× control) or 
adjusted-dose low-molecular-weight heparin (LMWH) 
(target anti-Xa level 4–6 hours post-dose 0.8-1.2 U/mL) 
started at the 36th week of gestation (Class I / Level C)  
● In pregnant women managed with LMWH, the post-
dose anti-Xa level should be assessed weekly (Class I / 
Level C)  
● LMWH should be replaced by IV UFH at least 36 
hours before planned delivery. UFH should be continued 
until 4–6 hours before planned delivery and restarted 4–6 
hours after delivery if there are no bleeding complications 
(Class I / Level C)  
● Immediate echocardiography is indicated in women 
with mechanical valves presenting with dyspnea and/or 
an embolic event (Class I / Level C)  
● Continuation of OACs should be considered during the 
first trimester if the warfarin dose required for therapeutic 
anticoagulation is <5 mg/day (or phenprocoumon <3 
mg/day or acenocoumarol <2 mg/day), after patient 
information and consent (Class IIa / Level C)  
● Discontinuation of OAC between weeks 6 - 12 and 
replacement by adjusted-dose UFH (a PTT ≥2× control; 
in high risk patients applied as IV infusion) or LMWH 
bid (with dose adjustment according to weight and target 
anti-Xa level 4–6 h post-dose 0.8–1.2 U/mL) should be 
considered in patients with a warfarin dose required of >5 
mg/d (or phenprocoumon >3 mg/d or acenocoumarol 
>2mg/d) (Class IIa / Level C)  
● Discontinuation of OACs between weeks 6 - 12 and 
replacement by UFH or LMWH under strict dose control 
(as described above) may be considered on an individual 
basis in patients with warfarin dose required for 
therapeutic anticoagulation <5 mg/d (or phenprocoumon 
<3 mg/d or acenocoumarol <2 mg/d) (Class IIb / Level C)  
● Continuation of OACs may be considered between 
weeks 6 - 12 in patients with a warfarin dose required for 
therapeutic anticoagulation >5 mg/d (or phenprocoumon 
>3 mg/d or acenocoumarol >2 mg/d) (Class IIb / Level C)  
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● LMWH should be avoided, unless anti-Xa levels are 
monitored  
 
Recommendations for the management of coronary 
artery disease 
● ECG and troponin levels should be performed in the 
case of chest pain in a pregnant woman (Class I / Level C)  
● Coronary angioplasty is the preferred reperfusion 
therapy for ST-elevation MI (STEMI) during pregnancy 
(Class I / Level C)  
● A conservative management should be considered for 
non ST-elevation acute coronary syndrome (ACS) 
without risk criteria (Class IIa / Level C)  
● An invasive management should be considered for non 
ST-elevation ACS with risk criteria (including non-
STEMI) (Class IIa / Level C)  
 
Recommendations for the management of 
cardiomyopathies (CM) and heart failure 
 
● Anticoagulation is recommended in patients with 
intracardiac thrombus detected by imaging or with 
evidence of systemic embolism (Class I / Level A)  
● Women with heart failure during pregnancy should be 
treated according to current guidelines for non-pregnant 
patients, respecting contraindications for some drugs in 
pregnancy (Class I / Level B)  
● Women with dilated CM (DCM) should be informed 
about the risk of deterioration of the condition during 
gestation and peripartum (Class I / Level C)  
● In patients with a past history or family history of 
sudden death close surveillance with prompt investigation 
is recommended if symptoms of palpitations or 
presyncope are reported (Class I / Level C)  
● Therapeutic anticoagulation with LMWH or vitamin K 
antagonists according to stage of pregnancy is 
recommended for patients with atrial fibrillation (AF) 
(Class I / Level C)  
● Delivery should be performed with β-blocker 
protection in women with hypertrophic CM (HCM) 
(Class IIa / Level C)  
● β-blockers should be considered in all patients with 
HCM and more than mild LV outflow tract obstruction or 
maximal wall thickness >15mm to prevent sudden 
pulmonary congestion (Class IIa / Level C)  
● In HCM, cardioversion should be considered for 
persistent AF (Class IIa / Level C)  
● Due to high metabolic demands of lactation and 
breastfeeding, preventing lactation may be considered in 
peri-partum CM (Class IIb / Level C)  
● Subsequent pregnancy is not recommended if LVEF 
does not normalize in women with peripartum CM  
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β-blockers: can be used during pregnancy; require close 
fetal monitoring for growth retardation; beta-1 selective 
antagonists preferred to avoid potential increased uterine 
tone and decreased uterine perfusion 
Digoxin: may be used if volume overload symptoms 
persist despite vasodilator and diuretic therapy 
Diuretics: may be used, but with caution regarding 
excessive volume contraction leading to reduced 
placental perfusion 
Hydralazine: may be used for management of heart 
failure symptoms or elevated blood pressure 
Nitrates: may be used to treat decompensated heart 
failure in pregnancy 
 
Recommendations for the management of arrhythmias 
 
Management of supraventricular tachycardia (SVT) 
 
● For acute conversion of paroxysmal SVT, vagal 
maneuver followed by IV adenosine is recommended 
(Class I / Level C)  
● Immediate electrical cardioversion is recommended for 
acute treatment of any tachycardia with hemodynamic 
instability (Class I / Level C)  
● For long-term management of SVT oral digoxin or 
metoprolol/propranolol is recommended (Class I/Level C) 
● For acute conversion of paroxysmal SVT, IV 
metoprolol or propranolol should be considered (Class IIa 
/ Level C)  
● For long-term management of SVT, oral sotalol or 
flecainide should be considered if digoxin or a β-blocking 
agent fails (Class IIa / Level C)  
● For acute conversion of paroxysmal SVT, IV verapamil 
may be considered (Class IIb / Level C)  
● For long-term management of SVT, oral propafenone, 
or procainamide may be considered as a last option if 
other suggested agents fail and before amiodarone is used 
(Class IIb / Level C)  
● For long-term management of SVT, oral verapamil 
may be considered for rate regulation if the other AV 
nodal-blocking agents fail (Class IIb / Level C)  
● Atenolol should not be used for any arrhythmia  
 
Management of ventricular tachycardia (VT) 
● The implantation of an ICD, if clinically indicated, is 
recommended prior to pregnancy but is also 
recommended whenever indicated, during pregnancy 
(Class I / Level C)  
● For long-term management of the congenital long QT 
syndrome, β-blocking agents are recommended during 
pregnancy and also postpartum when they have a major 
benefit (Class I / Level C)  
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● For long-term management of idiopathic sustained VT, 
oral metoprolol, propranolol or verapamil is 
recommended (Class I / Level C)  
● Immediate electrical cardioversion of VT is 
recommended for sustained, unstable, and stable VT 
(Class I / Level C)  
● For acute conversion of VT that is sustained, 
hemodynamically stable, and monomorphic, IV sotalol or 
procainamide should be considered (Class IIa / Level C)  
● Implantation of permanent pacemakers or ICDs 
(preferably single chamber) should be considered with 
echocardiographical guidance, especially if the fetus is 
beyond 8 weeks gestation (Class IIa / Level C)  
● For acute conversion of VT that is sustained, 
monomorphic, hemodynamically unstable, refractory to 
electrical cardioversion or not responding to other drugs, 
IV amiodarone should be considered (Class IIa / Level C)  
● For long-term management of idiopathic sustained VT, 
oral sotalol, flecainide, propafenone should be considered 
if other drugs fail (Class IIa / Level C)   
● Catheter ablation may be considered in the case of 
drug-refractory and poorly tolerated tachycardias (Class 
IIb / Level C) 
 
Recommendations for the management of Hypertension 
● Non-pharmacological management for pregnant 
women with systolic blood pressure (SBP) of 140-150 
mmHg or diastolic blood pressure (DBP) of 90-99 mmHg 
is recommended (Class I / Level C)  
● In women with gestational hypertension or pre-existing 
hypertension superimposed by gestational hypertension 
or with hypertension and subclinical organ damage or 
symptoms at any time during pregnancy, initiation of 
drug treatment is recommended at a blood pressure (BP) 
of 140/90 mmHg. In any other circumstances, initiation 
of drug treatment is recommended if SBP ≥150 mmHg or 
DBP ≥95 mmHg (Class I / Level C)  
● SBP ≥170 mmHg or DBP ≥110 mmHg in a pregnant 
woman is an emergency, and hospitalization is 
recommended (Class I / Level C)  
● Induction of delivery is recommended in gestational 
hypertension with proteinuria with adverse conditions 
such as visual disturbances, coagulation abnormalities, or 
fetal distress (Class I / Level C)  
● In pre-eclampsia associated with pulmonary edema, 
nitroglycerin given as an IV infusion, is recommended 
(Class I / Level C)  
● In severe hypertension, drug treatment with IV 
labetalol or oral methyldopa or nifedipine is 
recommended (Class I / Level C)  
● Women with pre-existing hypertension should be 
considered to continue their current medication except for 
ACE inhibitors, angiotensin receptor blockers (ARBs), 
and direct renin inhibitors under close BP-monitoring 
(Class IIa / Level C)  
 
Recent hypertension guidelines are in accordance 
with the above recommendations regarding hypertension 
management of pregnant women.43 It is indicated that the 
antihypertensive drugs to be used in pregnant 
hypertensive women may include methyldopa, labetalol 
and nifedipine as the only calcium antagonist really tested 
in pregnancy. Beta-blockers (implicated for fetal growth 
retardation if given in early pregnancy) and diuretics (in 
pre-existing reduction of plasma volume) should be used 
with caution. All agents involved in the renin-angiotensin 
system (ACE inhibitors, ARBs, renin inhibitors) should 
be avoided. In emergency situations, such as during pre-
eclampsia, IV labetalol is the drug of choice; IV sodium 
nitroprusside or nitroglycerin may be another option.42  
 
Recommendations for the prevention and management of 
venous thrombo-embolism (VTE) in pregnancy and 
puerperium 
 
● In all women who are pregnant or consider pregnancy, 
assessment of risk factors for VTE is recommended 
(Class I / Level C)  
● Mothers should be informed about the signs and 
symptoms of VTE in pregnancy and the necessity to 
contact the physicians if they occur (Class I / Level C)  
● High risk patients should receive antenatal prophylaxis 
with LMWH as well as post-partum for the duration of 6 
weeks (Class I / Level C)  
● In intermediate risk patients post-partum prophylaxis 
with LMWH should be given for at least 7 days or longer, 
if >3 risk factors persist (Class I / Level C)  
● In low risk patients early mobilization and avoidance of 
dehydration is recommended (Class I / Level C)  
● Graduated compression stockings are recommended 
antepartum and post-partum in all women at high risk 
(Class I / Level C)  
● D-Dimer measurement and compression 
ultrasonography is recommended in patients with 
suspected VTE during pregnancy (Class I / Level C)  
● For treatment of acute VTE during pregnancy, UFH is 
recommended in high-risk and LMWH in non-high risk 
patients (Class I / Level C)  
● Graduated compression stockings should be considered 
in women with intermediate risk during pregnancy and 
post-partum (Class IIa / Level C)  
 ●In intermediate risk patients, antenatal prophylaxis with 
LMWH should be considered (Class IIa / Level C)  
● Routine screening for thrombophilia should not be 
performed 
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CONCLUSION 
Cardiovascular disease (CVD) is the leading cause 
of maternal death and keeps rising. Pre-pregnancy 
diagnosis is most important. Women with pre-existing 
CVD should receive pre-pregnancy counselling to reduce 
morbidity and mortality; effective and safe contraceptive 
measures remain of paramount importance in patients 
with known CVD to avoid unplanned pregnancies. As 
ischemic heart disease increases in pregnancy, greater 
attention needs to be paid to risk factors in this group. 
Clinicians should have a low threshold for investigating 
any women complaining of chest pain and in particular if 
requiring significant analgesia. Recent advances have led 
to improved survival and function in patients with 
congenital heart disease (CHD) and to an increase in the 
number of women reaching child-bearing age. As 
experience in managing these patients during pregnancy 
has grown, the majority of patients with CHD can expect 
to get through pregnancy and delivery with acceptably 
low risk for complications. High-risk pregnancies should 
be managed in specializing centers by an experienced 
multidisciplinary team. Risk assessment tools are useful 
in determining the risk of women with CVD in 
pregnancy. Cardiac societies’ specific guidelines need to 
be adhered to.  
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